ID: MRFR/Pharma/1339-HCR | February 2021 | Region: Global | 80 pages
Valley Fever Market Scenario:
Valley fever which is also known as coccidioidomycosis, it is a fungal infection with the name Coccidioides fungus. This type of fungus is commonly found in soil and dust of various parts of the world mainly the Americas region.
The spores are most expected to appear in wet or warm soil after hefty rain fall. The bacteria are then tired into the air by anything that disturbs the soil, such as wind, construction, and farming. People can then contract valley fever by breathing in these tiny, airborne fungal bacteria. Globally the market for Valley Fever is expected to grow at the rate of about XX% from 2016 to 2022.
Valley Fever Market, by types of treatment
Study objectives of the Market:
Intended Audience
Key Finding
Segments:
Valley Fever market has been segmented on the basis of site of infection which comprises of skin, liver, bones, heart, brain, membranes that surround the brain and spinal cord and others. On the basis of treatments the market is segmented into fluconazole, itraconazole, voriconazole, posaconazole and others
Regional Analysis of the Market:
Globally Americas is the largest market for Valley Fever. Europe is expected to be the second-largest market
Frequently Asked Questions (FAQ) :
The site of infection in the valley fever includes fluconazole, voriconazole, posaconazole and others itraconazole,
Treatments discussed in the valley fever market are itraconazole, voriconazole, posaconazole fluconazole, and others.
The valley fever market has players like Anacor Pharmaceuticals, Novartis, , Valeant Pharmaceutical, Johnson and Johnson, GlaxoSmithKline Pharmaceuticals Limited, Galderma S.A., Pfizer Inc., Bristol Meyer Squibb, and others.
The Americas would hold the key of the valley fever market.
The treatment type segment would be dominated by Itraconazole.
1 Introduction
1.1 Definition
1.2 Scope of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porter’s five forces model
4.1.1 Bargaining Power of suppliers
4.1.2 Bargaining Power of Customer
4.1.3 Intensity of Competitor’s
4.1.4 Threat of New Entrants
5 Global Valley Fever Market, by Types of treatment
5.1 Introduction
5.1.1 Fluconazole
5.1.2 Itraconazole
5.1.3 Voriconazole
5.1.4 Posaconazole
5.1.5 Others
6 Global Valley Fever Market, by site of infection
6.1 Introduction
6.1.1 Skin
6.1.2 Liver
6.1.3 Heart
6.1.4 Bones
6.1.5 Others
7 Global Valley Fever Market, by regions
7.1 Introduction
7.1.1 North America
7.1.1.1 US
7.1.1.2 Canada
7.1.2 Europe
7.1.2.1 Germany
7.1.2.2 France
7.1.2.3 UK
7.1.2.4 Italy
7.1.2.5 Spain
7.1.2.5 Rest of Europe
7.1.3 Asia Pacific
7.1.3.1 Japan
7.1.3.2 China
7.1.3.3 India
7.1.3.4 South Korea
7.1.3.5 Rest of Asia Pacific
7.1.4 Middle East & Africa
8 Company Landscape
8.1 Introduction
8.1.1 Mergers Acquisitions
8.1.2 Collaborations
8.1.3 Release/New Product Launches
9 Company Profile
9.1 Novartis
9.1.1 Company Overview
9.1.2 Product/Business Segment Overview
9.1.3 Financials
9.1.4 Key Developments
9.2 Anacor Pharmaceuticals
9.2.1 Overview
9.2.2 Product/Business Segment Overview
9.2.3 Financials
9.2.4 Key Developments
9.3 Johnson and Johnson
9.3.1 Overview
9.3.2 Product/Business Segment Overview
9.3.3 Financials
9.3.4 Key Developments
9.4 Bristol Meyer Squibb
9.4.1 Overview
9.4.2 Product/Business Segment Overview
9.4.3 Financials
9.4.4 Key Developments
9.5 Valeant Pharmaceutical
9.5.1 Overview
9.5.2 Product/Business Segment Overview
9.5.3 Financials
9.5.4 Key Developments
10 Appendix